2025 H2 -tulosraportti
180 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·35 min sitten☢️ Everyone is chasing the next cancer medicine. But almost no one talks about who will supply the raw material. Targeted alpha therapy is red-hot, but has a gigantic logistics problem. Pb-212 has a half-life of only 10.6 hours. This is where Thor Medical (TRMED) becomes interesting. They deliver the mother isotope Th-228, so that Pb-212 can be produced locally – instead of being transported around before it has time to disappear. And the market could be enormous. 🎯 Targeted alpha therapy is expected to grow to around $2.25 billion by 2030, while the entire radiotherapeutics market could reach around $15 billion in 2030 and $28 billion in 2034. And Thor is already in position: 🏗️ AlphaOne is finished and in production. 🔥 Capacity has increased by 40 % after strong demand. 💰 ~850 MNOK in order backlog against a market capitalization of around 2.45 billion. 🤝 Several major radiopharma players have already signed long-term agreements. 🎯 On September 9, Jonas Gahr Støre officially opens AlphaOne. But there is a real competitor: Orano Med, which is building big and aiming for production from 2027. So what do you actually end up with? A company that has gone from technology → factory → production → customers. If targeted alpha therapy actually becomes a new standard in cancer treatment, the need for isotopes could explode. Thor is trying to own the infrastructure around it. ☢️- ·3 t sittenTHOR MEDICAL (TRMED) 🏭 No clinical studies that can fail. No ten years waiting for FDA. This is not biotech — it is pure industry. The facility is ready, the raw material is secured, and the order book is in place. With a prime minister's visit, official opening around the corner (and massive, free PR included), combined with the transition to commercial deliveries, this will be very exciting going forward.
·6 t sittenCool and symptomatic end to the day. The locomotive Thor Medical will not let you stop. The concept and realities in the company are too good for that.
·7 t sitten · MuokattuExciting days ahead for Thor Medical. The half-year report is coming on Friday. It will be exciting to see: - How many doses/deliveries have actually been made since the start-up. - If production is proceeding as planned technically and quality-wise. - If there are hints about AlphaTwo or further expansion (USA). - If management focuses on delivery capability and demand, or is more cautious. On September 9th, the Prime Minister officially opens the AlphaOne facility. That will likely generate increased media coverage going forward. We are still just in the initial phase :)
The half-year probably ended on June 30. Startup A1 approx 1.Aug, so we probably can't expect any info about production so far in Aug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
180 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sitten☢️ Everyone is chasing the next cancer medicine. But almost no one talks about who will supply the raw material. Targeted alpha therapy is red-hot, but has a gigantic logistics problem. Pb-212 has a half-life of only 10.6 hours. This is where Thor Medical (TRMED) becomes interesting. They deliver the mother isotope Th-228, so that Pb-212 can be produced locally – instead of being transported around before it has time to disappear. And the market could be enormous. 🎯 Targeted alpha therapy is expected to grow to around $2.25 billion by 2030, while the entire radiotherapeutics market could reach around $15 billion in 2030 and $28 billion in 2034. And Thor is already in position: 🏗️ AlphaOne is finished and in production. 🔥 Capacity has increased by 40 % after strong demand. 💰 ~850 MNOK in order backlog against a market capitalization of around 2.45 billion. 🤝 Several major radiopharma players have already signed long-term agreements. 🎯 On September 9, Jonas Gahr Støre officially opens AlphaOne. But there is a real competitor: Orano Med, which is building big and aiming for production from 2027. So what do you actually end up with? A company that has gone from technology → factory → production → customers. If targeted alpha therapy actually becomes a new standard in cancer treatment, the need for isotopes could explode. Thor is trying to own the infrastructure around it. ☢️
- ·3 t sittenTHOR MEDICAL (TRMED) 🏭 No clinical studies that can fail. No ten years waiting for FDA. This is not biotech — it is pure industry. The facility is ready, the raw material is secured, and the order book is in place. With a prime minister's visit, official opening around the corner (and massive, free PR included), combined with the transition to commercial deliveries, this will be very exciting going forward.
- ·6 t sittenCool and symptomatic end to the day. The locomotive Thor Medical will not let you stop. The concept and realities in the company are too good for that.
- ·7 t sitten · MuokattuExciting days ahead for Thor Medical. The half-year report is coming on Friday. It will be exciting to see: - How many doses/deliveries have actually been made since the start-up. - If production is proceeding as planned technically and quality-wise. - If there are hints about AlphaTwo or further expansion (USA). - If management focuses on delivery capability and demand, or is more cautious. On September 9th, the Prime Minister officially opens the AlphaOne facility. That will likely generate increased media coverage going forward. We are still just in the initial phase :)The half-year probably ended on June 30. Startup A1 approx 1.Aug, so we probably can't expect any info about production so far in Aug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
180 päivää sitten
‧38 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·35 min sitten☢️ Everyone is chasing the next cancer medicine. But almost no one talks about who will supply the raw material. Targeted alpha therapy is red-hot, but has a gigantic logistics problem. Pb-212 has a half-life of only 10.6 hours. This is where Thor Medical (TRMED) becomes interesting. They deliver the mother isotope Th-228, so that Pb-212 can be produced locally – instead of being transported around before it has time to disappear. And the market could be enormous. 🎯 Targeted alpha therapy is expected to grow to around $2.25 billion by 2030, while the entire radiotherapeutics market could reach around $15 billion in 2030 and $28 billion in 2034. And Thor is already in position: 🏗️ AlphaOne is finished and in production. 🔥 Capacity has increased by 40 % after strong demand. 💰 ~850 MNOK in order backlog against a market capitalization of around 2.45 billion. 🤝 Several major radiopharma players have already signed long-term agreements. 🎯 On September 9, Jonas Gahr Støre officially opens AlphaOne. But there is a real competitor: Orano Med, which is building big and aiming for production from 2027. So what do you actually end up with? A company that has gone from technology → factory → production → customers. If targeted alpha therapy actually becomes a new standard in cancer treatment, the need for isotopes could explode. Thor is trying to own the infrastructure around it. ☢️
- ·3 t sittenTHOR MEDICAL (TRMED) 🏭 No clinical studies that can fail. No ten years waiting for FDA. This is not biotech — it is pure industry. The facility is ready, the raw material is secured, and the order book is in place. With a prime minister's visit, official opening around the corner (and massive, free PR included), combined with the transition to commercial deliveries, this will be very exciting going forward.
- ·6 t sittenCool and symptomatic end to the day. The locomotive Thor Medical will not let you stop. The concept and realities in the company are too good for that.
- ·7 t sitten · MuokattuExciting days ahead for Thor Medical. The half-year report is coming on Friday. It will be exciting to see: - How many doses/deliveries have actually been made since the start-up. - If production is proceeding as planned technically and quality-wise. - If there are hints about AlphaTwo or further expansion (USA). - If management focuses on delivery capability and demand, or is more cautious. On September 9th, the Prime Minister officially opens the AlphaOne facility. That will likely generate increased media coverage going forward. We are still just in the initial phase :)The half-year probably ended on June 30. Startup A1 approx 1.Aug, so we probably can't expect any info about production so far in Aug.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt